Italy's antitrust regulator opens probe into US Biogen over alleged dominant position
27/05/2026 07:23
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position MILAN, May 27 (Reuters) - Italy's antitrust authority said on Wednesday it had opened an investigation into drug maker Biogen Italia and its parent Biogen BIIB.O over alleged abuse of dominant position.
The two companies allegedly aimed at excluding rival Sandoz SDZ.S from offering multiple sclerosis drugs, based on active ingredient natalizumab, the regulator said in a statement.
The watchdog carried out inspections at Biogen's Italian offices, assisted by Italy's finance police, it added.
Biogen was not immediately available for comment.
(Reporting by Cristina Carlevaro, editing by Giulia Segreti)
((cristina.carlevaro@thomsonreuters.com; +39 06 80307729;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout